TabMenu

Poverty and InequalitySexual and Reproductive HealthFamily, Maternal & Child HealthMethodology

Rationale and design of the Study To Understand Fall Reduction and Vitamin D in You (STURDY): A randomized clinical trial of Vitamin D supplement doses for the prevention of falls in older adults

TitleRationale and design of the Study To Understand Fall Reduction and Vitamin D in You (STURDY): A randomized clinical trial of Vitamin D supplement doses for the prevention of falls in older adults
Publication TypeJournal Article
Year of Publication2018
AuthorsMichos, ED, Mitchell, CM, Miller, E. R., 3rd, Sternberg, AL, Juraschek, SP, Schrack, JA, Szanton, SL, Walston, JD, Kalyani, RR, Plante, TB, Christenson, RH, Shade, D, Tonascia, J, Roth, DL, Appel, LJ
JournalContemp Clin Trials
Volume73
Pagination111-122
Date PublishedOct
ISBN Number1551-7144
Accession Number30138718
KeywordsAdaptive Design, Aging, Falls, randomized trial, vitamin D
Abstract

Prior evidence suggests that vitamin D supplementation may reduce fall risk, but existing data are inconsistent and insufficient to guide policy. We designed a two-stage Bayesian response-adaptive dose-finding and seamless confirmatory randomized trial of vitamin D supplementation to prevent falls. Up to 1200 community-dwelling persons, aged >/=70years, of predominantly white and African-American race, with serum 25(OH)D concentrations of 10-29ng/mL and at elevated fall risk, will be randomized to one of four vitamin D3 (cholecalciferol) supplement doses: 200 (control), 1000, 2000, or 4000IU/day and treated for up to 2years. Stage 1 is designed to identify the best of the non-control doses for fall prevention. If a best dose is selected, Stage 2 will start seamlessly, with enrollees assigned to control or the best dose in Stage 1 continuing on that dose unchanged, enrollees assigned to the two non-control, non-best doses in Stage 1 switched to the best dose, and new enrollees randomly assigned 1:1 to control or the best dose. In Stage 2, we will compare the control dose group to the best dose group to potentially confirm the efficacy of that dose for fall prevention. The primary outcome measure in both stages is time to first fall or death, whichever comes first. Falls are ascertained from calendars, scheduled interviews, or interim self-reports. Secondary outcome measures include time to each component of the composite primary outcome and gait speed. Additional outcomes include the Short Physical Performance Battery score, physical activity level (assessed by accelerometry), and frailty score. CLINICAL TRIAL REGISTRATION: NCT02166333.

PMCID

PMC6251709